Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Table 1

The characteristic of studies (n = 14).

Author	Country	Study design	Year	Age (yrs)	Male	Number of population	NOS/AHRQ	Stage of CKD	Pathogeny
Pawlak et al. [23]	Poland	Cross-sectional	2007	58.5 ± 12.3	38	64	7	5	1, 2, 3, 4, 5, 11
Pawlak et al. [24]	Poland	Cross-sectional	2010	53.3 ± 15.3	43	70	6	5	1, 2, 3, 4, 5, 6, 11
Pawlak et al. [25]	Poland	Cross-sectional	2012	54.5 ± 14.3	35	60	7	1–5	1, 2, 3, 4, 6, 11
Bock et al. [26]	America	Cross-sectional	2013	12.1 ± 5.0	43	99	10	NA	1, 10, 11
Hayek et al. [12]	America	Cohort	2015	63 ± 12	2404	3683	8	NA	NA
Meijers et al. [13]	Belgium	Cohort	2015	61 ± 5.8	260	476	7	1–4	NA
Drechsler et al. [14]	Germany	Cohort	2017	66 ± 8	635	1175	6	5	6
Schaefer et al. [27]	European	Cohort	2017	11.9 ± 3.5	560	898	7	NA	1, 10, 11
Kaminski et al. [28]	Poland	Cross-sectional	2018	52.9 ± 15.7	26	65	7	1–5	NA
Luo et al. [29]	America	Cohort	2018	55 ± 11	582	955	6	NA	NA
Lv et al. [30]	China	Cohort	2018	48.2 ± 13.8	1402	2391	7	3–4	1, 6, 11
Wlazel et al. [31]	Poland	Cohort	2018	66.7 ± 13	42	64	7	4–5	2, 3, 5, 6, 7, 8
Wu et al. [32]	China	Cohort	2018	52.0 ± 14.3	53	99	7	4–5	1, 3, 5, 6, 7, 9, 11
Rotbain curovic et al. [33]	Denmark	Cohort	2019	56 ± 12	178	667	7	NA	6

1, chronic glomerulonephritis; 2, interstitial nephritis; 3, polycystic kidney disease; 4, secondary amyloidosis; 5, hypertensive nephropathy; 6, diabetes mellitus; 7, obstructive nephropathy; 8, ischemic nephropathy; 9, renal tumor; 10, nonglomerular diseases; 11, other renal disease; NA : not applicable.